Summary
68 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It has been profitable 6 years in a row.
What to watch
- It cut its dividend by 11% last year.
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 7.3% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 23.8 USD for 1 USD of yearly profit. Over the last five years it was 26.9 USD on average.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.0% a year over 5 years. Over the last 3 years it grew by 2.6% a year. For the next fiscal year analysts expect revenue to grow by 7.6%. Earnings per share fell by 7.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 37 USD
- Research and development 7.8 USD
- Sales and administration 34 USD
- Taxes and other 6.7 USD
- Net profit 14 USD
Net profit, industry median (Medical - Devices) 6.5 USD
Out of every 100 USD of revenue, 14 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.85%
- Paid out of profit
- 68%
You receive 2.48 € per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 30
- Hold 19
- Sell 0
No analyst has published a price target.
61% of the analysts recommend buying.
Analysts in detail